$3.19
0.31%
Nasdaq, Nov 17, 03:58 pm EST. Closed.
ISIN
US0887861088
Symbol
BCYC

Bicycle Therapeutics Plc Stock price

$3.20
-0.34 9.48% 1M
-1.16 26.61% 6M
-3.88 54.80% YTD
-3.26 50.46% 1Y
-10.65 76.90% 3Y
-57.66 94.74% 5Y
-10.80 77.14% 10Y
-10.80 77.14% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
+0.02 0.63%
ISIN
US0887861088
Symbol
BCYC
Industry

Is Bicycle Therapeutics Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$235.9m
Enterprise Value
$-233.3m
Net debt
positive
Cash
$469.9m
Shares outstanding
70.0m
Valuation
P/E
negative
P/S | estimate
2.8 | 15.0
EV/Sales | estimate
negative | negative
EV/FCF | ex SBC
1.3 | 1.1
P/B
0.5
Financial Health
Equity Ratio
85.0%
Return on Equity
-35.9%
ROCE
-30.3%
ROIC
-185.4%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$30.4m | 36.4%
SBC as % of FCF
-
SBC Growth 1Y
-20.3%
Share Count Growth 1Y
1.0%
Shareholder Yield
-1.0%
Financials
Revenue | estimate
$83.5m | $15.7m
EBITDA
$-153.7m
EBIT
$-158.3m
Net Income
$-141.8m
Free Cash Flow | ex SBC
$-177.0m | $-207.4m
Growth
Revenue | estimate
194.7% | -78.4%
EBITDA
44.9%
EBIT
44.6%
Net Income
43.4%
Free Cash Flow
26.8%
Margin
Gross
-
EBITDA
-184.1%
EBIT
-189.6%
Net
-169.8%
Free Cash Flow | ex SBC
-212.0% | -248.4%
More
EPS
$-2.0
FCF per Share
$-2.5
Short interest
9.9%
Employees
288
Rev per Employee
$250.0k

Bicycle Therapeutics Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Bicycle Therapeutics Plc forecast:

12x Buy
75%
4x Hold
25%

Analyst Opinions

16 Analysts have issued a Bicycle Therapeutics Plc forecast:

Buy
75%
Hold
25%

Financial data from Bicycle Therapeutics Plc

Sep '26
+/-
%
84 84
195% 195%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 67 67
17% 17%
80%
- Research and Development Expense 175 175
26% 26%
210%
-154 -154
45% 45%
-184%
- Depreciation and Amortization 4.61 4.61
32% 32%
6%
EBIT (Operating Income) EBIT -158 -158
45% 45%
-190%
Net Profit -142 -142
43% 43%
-170%

In millions USD.

Don't miss a Thing! We will send you all news about Bicycle Therapeutics Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bicycle Therapeutics Plc Stock News

Neutral
Business Wire
●
19 days ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2026, and provided recent corporate updates. “We are pleased with the continued progres...
Positive
PYMNTS
●
4 months ago
Visa is set to acquire Israel-based fraud intelligence company BioCatch for $2.4 billion. The all-cash deal, announced Monday (Aug. 3) aims to complement Visa's cyber, fraud, risk and security solutions and help clients protect themselves and customers from a growing range of fraud-related threats.
Neutral
Business Wire
●
4 months ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. “We are pleased with the progress we made duri...
More Bicycle Therapeutics Plc News

Company Profile

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Dr. Lee
Employees 288
Founded 2009
Website www.bicycletherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today